Summary of Passage Bio FY Conference Call Company Overview - **Company**: Passage Bio (NasdaqGS:PASG) - **Focus**: Development of gene therapies for neurodegenerative diseases, specifically targeting Frontotemporal Dementia (FTD) with granulin mutation and Huntington's disease Key Points Clinical Programs - **FTD-GRN Program**: - Targets Frontotemporal Dementia (FTD) with granulin mutation affecting approximately 18,000 patients in the U.S. and Europe [2] - FTD is characterized by early-onset behavioral dementia with no current treatment options, leading to an average lifespan of eight years post-diagnosis [2] - The program aims to address low levels of progranulin, a protein critical for lysosomal function, which is deficient in these patients due to granulin gene mutation [2][3] - The AAV1 gene therapy product aims to replace the missing progranulin to improve neurodegeneration outcomes [3] - **Study Progress**: - Nine patients have been treated in the ongoing Phase 1/2 study, with modifications to inclusion criteria to focus on milder cases of FTD [4] - The study is assessing safety, tolerability, and biomarkers such as CSF progranulin levels, plasma neurofilaments, and volumetric MRI [5][6] - Initial data shows that higher doses of the therapy significantly elevate CSF progranulin levels, with expectations for lower doses to also show positive trends [8][9] - **Safety Profile**: - Three serious adverse events (SAEs) were reported at the higher dose, leading to a shift to a lower dose and the introduction of prophylactic anticoagulation [10][12] - The safety profile remains a critical focus as the company prepares for regulatory discussions [39] Competitive Landscape - **Comparison with Other Therapies**: - Passage Bio's approach is differentiated from other therapies, such as the anti-sortilin antibody therapy, which did not meet endpoints in clinical trials [23] - The company emphasizes the importance of patient selection and the mechanistic differences in their therapy compared to competitors [24][28] Future Outlook - **Regulatory Strategy**: - The company is seeking early regulatory feedback on the registrational path for FTD-GRN, considering both single-arm and randomized controlled study designs [38] - Plans to declare a clinical candidate for Huntington's disease in the second half of the year, with ongoing discussions about the development path [16][52] - **Enrollment and Interest**: - Enrollment for the FTD-GRN cohort has been brisk, with increased interest following the discontinuation of other studies in the space [44][50] - The company is optimistic about the momentum in patient recruitment due to the unmet need in the orphan indication [50] Manufacturing and Partnerships - **Manufacturing Process**: - The company has established an efficient manufacturing process for its gene therapies, which is crucial for scaling production [59] - Current manufacturing capabilities are focused on the FTD program, with plans to expand as the Huntington's program develops [60] Additional Insights - The company is committed to addressing neurodegenerative diseases through innovative gene therapy approaches, with a focus on safety and efficacy as they navigate regulatory pathways and clinical development [59][60]